1. Алиев В.А., Барсуков Ю.Ю., Николаев А.В. Колоректальный рак с синхронными отдаленными метастазами: обоснование циторедуктивных операций и перспектив - взгляд хирурга. Онкологическая колопроктология. 2012; 4: 15-20.
2. Горчаков С.В., Правосудов И.В., Васильев С.В., Олейник В.В., Оношко М.В., Попов Д.Е. Современные подходы к лечению больных колоректальным раком с метаста зами в печень. Вестник Санкт-Петербургского университета. Медицина. 2015; 3: 55-68.
3. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Московский научно-исследовательский онкологический институт имени П.А. Герцена. М., 2017. 250 c.
4. Трякин А.А., Артамонова Е.В., Болотина Л.В. Колоректальный рак. RUSSCO, 2016. С. 266-285.
5. Adenis A., de la Fouchardiere C., Paule B., Burtin P., Tougeron D., Wallet J., Dourthe L.M., Etienne P.L., Mineur L., Clisant S., Phelip J.M., Kramar A., Andre T. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016; 16 (7): 412-420. https://doi.org/10.1186/s12885-016-2440-9
6. Ychou M., Viret F., Kramar A., Desseigne F., Mitry E., Guimbaud R., Delpero J.R., Rivoire M., Quénet F., Portier G., Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother. Pharmacol. 2008; 62 (2): 195-201.
7. Гранов А.М., Давыдов М.И. Интервенционная радиология в онкологии (пути развития и технологии). Под ред. Таразова П.Г., Гранова Д.А. 2-е изд., доп. СПб., 2013. 546 с.
8. Bhutiani N., Martin R.C. Transarterial therapy for colorectal liver metastases. Surg. Clin. North. Am. 2016; 96 (2): 369-391. https://doi.org/10.1016/j.suc.2015.12.003
9. Bhutiani N., Akinwande O., Martin R. Efficacy and toxicity of hepatic intra-arterial drug-eluting (Irinotecan) bead (DEBIRI) therapy in Irinotecan-refractory unresectable colorectal liver metastases. World J. Surg. 2016; 40 (5): 1178-1190. https://doi.org/10.1007/s00268-015-3386-9
10. Scevola G., Loreni G., Rastelli M., Sposato S., Ramponi S., Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med. Oncol. 2017; 34 (3): 37-41. https://doi.org/10.1007/s12032-017-0890-9
11. Vogl T.J., Lahrsow M., Albrecht M.H., Hammerstingla R., Thompsonb Z.M., Gruber-Rouh T. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. Eur. J. Radiol. 2018; 102 (5): 138-145. https://doi.org/10.1016/j.ejrad.2018.03.015
12. Gennari L., Doci R., Bozzetti F., Veronesi U. Proposal for a clinical classification of liver metastases. Tumori. 1982; 68 (5): 443-449.
13. Konopke R., Roth J., Volk A., Pistorius S., Folprecht G., Zoephel K., Schuetze C., Laniado M., Saeger H., Kersting S. Colorectal liver metastases: an update on palliative treatment options. J. Gastrointest. Liver Dis. 2012; 21 (1): 83-91.
14. Schiergens T.S., von Einem J., Thomas M.N. Multidisciplinary treatment of colorectal liver metastases. Minerva Med. 2017; 108 (6): 527-546. https://doi.org/10.23736/S0026-4806.17.05371-X
15. Fiorentini G., Aliberti C., Sarti D., Coschiera P., Tilli M., Mulazzani L., Giordani P., Graziano F., Gonzalez A.M., Marcos R.G., Mugnoz F.G., Cantore M., Ricci S., Catalano V., Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J. Gastrointest. Oncol. 2015; 15 (6): 47-54. https://doi.org/10.4251/wjgo.v7.i6.47
16. van Hazel G., Pavlakis N., Goldstein D., Olver I.N., Tapner M.J., Price D., Bower G.D., Briggs G.M., Rossleigh M.A., Taylor D.J., George J. et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J. Clin. Oncol. 2009; 7 (25): 4089-4095. https://doi.org/10.1200/JCO.2008.20.8116
17. Cercek A., Boucher T., Gluskin J., Aguiló A., Chou J.F., Connell L.C., Capanu M., Reidy-Lagunes D., D'Angelica M., Kemeny N.E. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J. Surg. Oncol. 2016; 114 (6): 655-663. https://doi.org/10.1002/jso.24399
18. Arai Y., Aoyama T., Inaba Y., Okabe H., Ihaya T., Kichikawa K., Ohashi Y., Sakamoto J., Oba K., Saji S. Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study). Asia Pac. J. Clin. Oncol. 2015; 11 (1): 41-48. https://doi.org/10.1111/ajco.12324
19. Massmann A., Rodt T., Marquardt S., Seidel R., Thomas K., Wacker F., Richter G.M., Kauczor H.U., Bücker A., Pereira P.L., Sommer C.M. Transarterial chemoembolization (TACE) for colorectal liver metastases - current status and critical review. Langenbeck’s Arch. Surg. 2015; 400 (6): 641-659. https://doi.org/10.1007/s00423-015-1308-9
20. Gruber-Rouh T., Naguib N., Eichler K., Naguib N.N., Beeres M., Langenbach M., Vogl T.J. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int. J. Cancer. 2014; 134 (5): 1225-1231. https://doi.org/10.1159/000488644
21. Goi T., Naruse T., Kimura Y., Morikawa M., Koneri K., Yamaguchi A. Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. World J. Surg. Oncol. 2015; 13 (9): 296. https://doi.org/10.1186/s12957-015-0704-5
22. Zervoudakis A., Boucher T., Kemeny N. Treatment options in colorectal liver metastases: hepatic arterial infusion. Visc. Med. 2017; 33 (1): 47-53. https://doi.org/10.1159/000454693